BLIS K12 Receives “No Objection” GRAS Letter From FDA

635914720924384696taste.jpg

19 Feb 2016 --- Oral-health probiotic BLIS K12 has received a “Letter of No Objection” from the US Food and Drink Administration (FDA) for its self-affirmed notification of Generally Recognized As Safe (GRAS) status.

The patented probiotic strain of Streptococcus salivarius, BLIS K12, has been studied for benefits to ear and throat health in children and adults, including reducing incidence of halitosis and Streptococal pharyngitis.
 
BLIS K12 developer Blis Technologies (Dunedin, New Zealand) and North America distributor Stratum Nutrition (Saint Charles, MO) celebrated the “No Objection” GRAS status as key to opening more markets for the probiotic:
 
“It adds a new level of credibility for BLIS K12 and puts the conversations with larger consumer food and beverage companies in the US on a stronger footing,” said Peter Fennessy, board chairman, Blis Technologies.
 
“Many of those companies are, quite rightly, risk averse. Therefore, having the non-objection notification from the FDA offers an additional level of confidence and makes it clearer where BLIS K12 fits within the category,” Fennessy added.
 
Jeremy Moore, managing director of Stratum Nutrition, added, “Very few ingredients in this space go to this level, so it is a definite feather in the cap for Blis.”
 
Through the GRAS program, companies may submit their determination, supported by research and expert review, that a specific ingredient is Generally Recognized As Safe. The Letter of No Objection means that the FDA has reviewed the data and has no questions regarding the notice submitted.

Related Articles

Business News

Lakeview Equity invests in nutritional solutions provider NutriScience Innovations

11 Dec 2017 --- Lakeview Equity Partners, LLC, a US$40 million Milwaukee, US-based private equity fund, has invested in NutriScience Innovations, LLC, based in Trumbull, Connecticut, US. NutriScience is a cGMP-certified global supplier of nutritional and functional ingredients to companies that manufacture nutraceutical, pharmaceutical, food and beverage, and dietary products.

Business News

New Biopolis probiotic mix helps reduce topical steroid use by atopic dermatitis patients

07 Dec 2017 --- Biopolis, majority owned by agricultural processor and food ingredient provider Archer Daniels Midland Company (ADM), has introduced a new probiotic mix designed to reduce the need for topical steroid use by Atopic Dermatitis (AD) patients. The clinical research recently published in JAMA Dermatology, an international peer-reviewed general medical journal, shows the benefits of consuming a mix of probiotics in reducing the need for topical steroids by AD patients.

Business News

Nestle acquires Atrium for US$2.3 billion, extends consumer healthcare portfolio

06 Dec 2017 --- Nestle has agreed to acquire Canadian nutritional health products manufacturer Atrium Innovations from a group of investors led by Permira Funds for US$2.3 billion in cash. Nestle notes that the move for the company, whose 2017 sales are expected to reach almost US$700 million, supports Nestle’s pursuit of growth opportunities in consumer healthcare to complement the company's focus on its high-growth food and beverage categories.

Nutrition & Health News

DuPont’s Microbiome Venture aims to lead development of new microbiome science-based solutions

30 Nov 2017 --- DuPont Nutrition & Health has announced the development of what it describes as a “significant new initiative” with the creation of its Microbiome Venture to spearhead the development of new microbiome science-based solutions. The Microbiome Venture will play a key role in DuPont’s business growth strategy.

Nutrition & Health News

Modifying gut microbiome may eventually prevent asthma in infant boys

29 Nov 2017 --- The family risk for asthma – typically passed from mothers to babies – may involve the microbes found in a baby's digestive tract. This is according to a new University of Alberta study, funded by the Canadian Institutes of Health Research (CIHR) and AllerGen and published in the European Respiratory Journal.

More Articles
URL : http://www.nutritioninsight.com:80/news/blis-k12-receives-no-objection-gras-letter-from-fda.html